KR102020072B1 - 진단 항체 시험 - Google Patents

진단 항체 시험 Download PDF

Info

Publication number
KR102020072B1
KR102020072B1 KR1020137023118A KR20137023118A KR102020072B1 KR 102020072 B1 KR102020072 B1 KR 102020072B1 KR 1020137023118 A KR1020137023118 A KR 1020137023118A KR 20137023118 A KR20137023118 A KR 20137023118A KR 102020072 B1 KR102020072 B1 KR 102020072B1
Authority
KR
South Korea
Prior art keywords
antibody
antibodies
cells
val
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137023118A
Other languages
English (en)
Korean (ko)
Other versions
KR20140006019A (ko
Inventor
마틴 클라인슈미트
슈테판 쉴링
옌스-울리히 라펠트
한스-울리히 데무스
크리스틴 에버만
Original Assignee
프로비오드룩 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로비오드룩 아게 filed Critical 프로비오드룩 아게
Publication of KR20140006019A publication Critical patent/KR20140006019A/ko
Application granted granted Critical
Publication of KR102020072B1 publication Critical patent/KR102020072B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
KR1020137023118A 2011-03-16 2012-03-16 진단 항체 시험 Expired - Fee Related KR102020072B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161453449P 2011-03-16 2011-03-16
US61/453,449 2011-03-16
PCT/EP2012/054629 WO2012123562A1 (en) 2011-03-16 2012-03-16 Diagnostic antibody assay

Publications (2)

Publication Number Publication Date
KR20140006019A KR20140006019A (ko) 2014-01-15
KR102020072B1 true KR102020072B1 (ko) 2019-11-04

Family

ID=45833428

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137023118A Expired - Fee Related KR102020072B1 (ko) 2011-03-16 2012-03-16 진단 항체 시험

Country Status (15)

Country Link
US (2) US8809508B2 (enExample)
EP (1) EP2686346B1 (enExample)
JP (1) JP6220675B2 (enExample)
KR (1) KR102020072B1 (enExample)
CN (1) CN103459421B (enExample)
AU (1) AU2012228236B2 (enExample)
BR (1) BR112013023211B1 (enExample)
CA (1) CA2828433C (enExample)
DK (1) DK2686346T3 (enExample)
EA (1) EA032054B1 (enExample)
IL (1) IL227847A0 (enExample)
MX (1) MX343873B (enExample)
SG (1) SG192805A1 (enExample)
WO (1) WO2012123562A1 (enExample)
ZA (1) ZA201305946B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240041740A (ko) * 2022-09-23 2024-04-01 경성대학교 산학협력단 베타-아밀로이드 42를 이용한 치매 진단 방법 및 이를 이용한 치매 진단 키트

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970235B1 (en) 2013-03-15 2019-06-19 Probiodrug AG Novel inhibitors
US20170363645A1 (en) 2014-12-19 2017-12-21 Probiodrug Ag Novel Method for the Detection of pGlu-Abeta Peptides
WO2016137947A1 (en) * 2015-02-24 2016-09-01 Rpeptide, Llc Anti-amyloid-beta antibodies
CA2992386A1 (en) * 2015-07-16 2017-01-19 Probiodrug Ag Humanized antibodies
GB201910697D0 (en) * 2019-07-26 2019-09-11 Binding Site Group Ltd Lonisation control
AU2020357863B2 (en) * 2019-10-01 2023-07-06 Repligen Corporation Determination of protein concentration in a fluid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100021478A1 (en) * 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
WO2010128139A1 (en) * 2009-05-08 2010-11-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
ES2275570T3 (es) * 1999-12-08 2007-06-16 Intellect Neurosciences, Inc. Peptidos amiloides beta quimericos.
US7117096B2 (en) * 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
AU2003250102B2 (en) 2002-07-24 2009-09-17 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2004029629A1 (en) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
US7304086B2 (en) 2004-02-05 2007-12-04 Probiodrug Ag Inhibitors of glutaminyl cyclase
ES2259270B1 (es) 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
US20100028351A1 (en) 2006-06-29 2010-02-04 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
DK2086960T3 (da) 2006-11-09 2014-06-10 Probiodrug Ag Nye inhibitorer af glutaminylcyclase.
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
DK2091945T3 (da) 2006-11-09 2014-04-22 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
JP5612860B2 (ja) 2007-03-09 2014-10-22 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのイミダゾ［１，５−ａ］ピリジン誘導体
WO2008128982A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors
WO2008128986A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Urea derivatives as glutaminyl cyclase inhibitors
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
WO2008128981A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors
DK2160380T3 (da) 2007-04-18 2014-06-30 Probiodrug Ag Cyano-guanidin derivater som glutaminyl cyclase inhibitorer
US8188094B2 (en) 2007-04-20 2012-05-29 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008312611A1 (en) * 2007-10-15 2009-04-23 Centocor, Inc. Human anti-amyloid antibodies, compositions, methods and uses
AT506820B1 (de) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
PL2448968T3 (pl) * 2009-06-29 2021-09-13 Bioarctic Ab Antybiotyki selektywne względem n-końcowych skróconych protofibryli/oligomerów amyloidu beta

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100021478A1 (en) * 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
WO2010128139A1 (en) * 2009-05-08 2010-11-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Biomarkers and methods for diagnosing alzheimer's disease and/ or mild cognitive impairment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neuroscience Letters. Vol. 215, No. 3, pp. 173-176 (1996)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240041740A (ko) * 2022-09-23 2024-04-01 경성대학교 산학협력단 베타-아밀로이드 42를 이용한 치매 진단 방법 및 이를 이용한 치매 진단 키트
KR102790945B1 (ko) 2022-09-23 2025-04-04 경성대학교 산학협력단 베타-아밀로이드 42를 이용한 치매 진단 방법 및 이를 이용한 치매 진단 키트

Also Published As

Publication number Publication date
BR112013023211A2 (pt) 2016-11-22
SG192805A1 (en) 2013-09-30
ZA201305946B (en) 2014-10-29
US20120237529A1 (en) 2012-09-20
EP2686346B1 (en) 2016-12-14
KR20140006019A (ko) 2014-01-15
MX2013010571A (es) 2013-12-02
US8809508B2 (en) 2014-08-19
JP6220675B2 (ja) 2017-11-01
MX343873B (es) 2016-11-25
US9657089B2 (en) 2017-05-23
EA032054B1 (ru) 2019-04-30
CN103459421A (zh) 2013-12-18
IL227847A0 (en) 2013-09-30
US20140255414A1 (en) 2014-09-11
EA201301029A1 (ru) 2014-05-30
CN103459421B (zh) 2017-07-14
EP2686346A1 (en) 2014-01-22
JP2014509860A (ja) 2014-04-24
CA2828433A1 (en) 2012-09-20
CA2828433C (en) 2020-08-04
DK2686346T3 (en) 2017-03-27
WO2012123562A1 (en) 2012-09-20
BR112013023211B1 (pt) 2022-11-08
AU2012228236B2 (en) 2016-10-27
NZ614217A (en) 2015-12-24
AU2012228236A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
KR101706789B1 (ko) 진단용 항체 검사법
KR102020072B1 (ko) 진단 항체 시험
CN108699139B (zh) 人源化抗体
EP2328930B1 (en) Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe)
HK1192568B (en) Diagnostic antibody assay
HK1192568A (en) Diagnostic antibody assay
NZ614217B2 (en) Diagnostic antibody assay
EA043617B1 (ru) Гуманизированные и деиммунизированные антитела
HK40036167B (zh) 人源化和去免疫化抗体
HK1158946B (en) Diagnostic antibody assay

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240904

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240904